Invagen Pharmaceuticals Inc has entered into a strategic partnership with Qilu Pharmaceutical Co., for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda (pembrolizumab), for the US.

As part of the agreement, Qilu will be responsible for development, regulatory registration and supply of the product while Cipla USA Inc. will be responsible for the commercialisation of the asset by leveraging its strong commercial presence in the defined territory.

Commenting on the partnership, Achin Gupta, Managing Director and Global Chief Executive Officer, Cipla, said, “This partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio. By combining Qilu’s development strengths with Cipla’s commercial presence and patient-centric legacy, we aim to expand access to high-quality biologics for patients across our focus markets.”

The collaboration reflects both companies’ shared commitment to addressing the growing burden of cancer and improving access to advanced biologic therapies.

Hanchang Zhang, General Manager (GM), Qilu Pharmaceutical, said, “We are pleased to establish this partnership with Cipla for QL2107. Qilu boasts a robust and growing biosimilar product pipeline. By combining our R&D and manufacturing strengths with Cipla’s US commercial expertise, we aim to bring a high-quality, affordable pembrolizumab biosimilar to US patients.”